共 50 条
The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate
被引:3
作者:
Clotaire, Laetitia
[1
,2
]
Rubera, Isabelle
[1
]
Duranton, Christophe
[1
]
Gal, Jocelyn
[3
]
Chamorey, Emmanuel
[3
]
Humeau, Helene
[4
]
Yamani, Samir
[5
]
Chiaverini, Christine
[6
]
Willoteaux, Serge
[7
]
Padovani, Bernard
[8
]
Mourozeau, Laurie
[4
]
Mainguy, Adam
[4
]
Baillif, Stephanie
[9
]
Martin, Ludovic
[10
,11
]
Leftheriotis, Georges
[1
,12
]
机构:
[1] Univ Cote Azur, CNRS, LP2M, Nice, France
[2] Labs ProNutri, Res & Dev Dept, Carros, France
[3] Ctr Antoine Lacassagne, Stat Dept, Nice, France
[4] Ctr Hosp Univ Angers, Ophthalmol Dept, Angers, France
[5] Cote Azur Univ, Ctr Hosp Univ Nice, Dept Dermatol, Nice, France
[6] Univ Cote Azur, Ctr Hosp Univ Nice, Dermatol Dept, Nice, France
[7] Ctr Hosp Univ Angers, Radiol Dept, Angers, France
[8] Univ Cote Azur, Ctr Hosp Univ Nice, Radiol Dept, Nice, France
[9] Univ Cote Azur, Ctr Hosp Univ Nice, Ophthalmol Dept, Nice, France
[10] Ctr Hosp Univ Angers, PXE Natl Reference Ctr, Angers, France
[11] Ctr Hosp Univ Angers, Dermatol Dept, Angers, France
[12] Univ Cote Azur, Natl Ctr Rare Arterial Dis, Ctr Hosp Univ Nice, Nice, France
来源:
关键词:
Double-blind randomized clinical trial;
Pyrophosphate supplementation;
Arterial calcification;
Pseudoxanthoma elasticum;
ECTOPIC MINERALIZATION;
TISSUE;
CALCIFICATION;
PLASMA;
D O I:
10.1186/s13063-024-08666-w
中图分类号:
R-3 [医学研究方法];
R3 [基础医学];
学科分类号:
1001 ;
摘要:
Background/aims.Pseudoxanthoma Elasticum (PXE, OMIM 264800) is an autosomal, recessive, metabolic disorder characterized by progressive ectopic calcification in the skin, the vasculature and Bruch's membrane. Variants in the ABCC6 gene are associated with low plasma pyrophosphate (PPi) concentration. There is currently no reference treatment for this chronic debilitating disease.Background/aims.Pseudoxanthoma Elasticum (PXE, OMIM 264800) is an autosomal, recessive, metabolic disorder characterized by progressive ectopic calcification in the skin, the vasculature and Bruch's membrane. Variants in the ABCC6 gene are associated with low plasma pyrophosphate (PPi) concentration. There is currently no reference treatment for this chronic debilitating disease.MethodsPROPHECI (PyROphosPHate supplementation to fight ECtopIc calcification in PseudoXanthoma Elasticum) is the first phase II, randomized, double-blind, placebo-controlled clinical trial (NTC 04868578) to evaluate the efficacy and safety of a daily oral PPi salt supplementation to attenuate and/or stabilize the progression of ectopic calcification in PXE patients. The primary endpoint is the change in arterial calcification volume quantified by non-contrast CT scan between baseline and 12 months of treatment. Secondary endpoints include the safety and efficacy of daily oral PPi administration on ocular and skin lesions and the evaluation of patients' quality of life.DiscussionThe PROPHECI trial aims to provide safety and efficacy data on the use of daily oral PPi to reduce or stabilize ectopic calcification in PXE. It also aims to validate the best markers to include in the design of future trials for the treatment of PXE and other parent diseases.Trial registrationTrial registration number: NCT 04868578.References can be found on the ClinicalTrials.gov website: https://clinicaltrials.gov/study/NCT04868578?cond=Pseudoxanthoma%20Elasticum&intr=pyrophosphate&rank=2Trial registrationTrial registration number: NCT 04868578.References can be found on the ClinicalTrials.gov website: https://clinicaltrials.gov/study/NCT04868578?cond=Pseudoxanthoma%20Elasticum&intr=pyrophosphate&rank=2
引用
收藏
页数:12
相关论文
共 50 条